Lung transplant patients may get better flu protection with high-dose vaccine
NCT ID NCT05215327
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares a high-dose flu vaccine to the standard dose in 270 lung transplant recipients who are 1 to 35 months post-transplant. The goal is to see if the high-dose vaccine triggers a stronger immune response and provides better protection against influenza. Participants will receive two doses of either vaccine within the same flu season.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNIZATION; INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Vanderbilt University Medical Center
RECRUITINGNashville, Tennessee, 37232, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Flu vaccine showdown: which shot protects seniors best?
- Can a simple breath test catch flu in High-HIV regions?
- Can a simple mask stop the flu? 2,000 volunteers put it to the test
- Can a stronger flu shot better protect seniors?
- Flu shot showdown: Cell-Grown vs recombinant vaccine put to the test
- A new drug combo may shield kidney transplant patients from a common viral threat